GoKawiilFDA clears WashU-derived PrecivityAD2 blood test for Alzheimer's diagnosis
The FDA has cleared PrecivityAD2, a blood test built on technology from Washington University School of Medicine, to help identify amyloid plaques linked to Alzheimer's disease. Developed by WashU spinoff C2N Diagnostics, the test uses high-resolution mass spectrometry to quantify biomarkers with over 90% accuracy, offering a less invasive option than spinal taps or brain imaging.